Is idelalisib a chemotherapy?
Idelalisib is the generic name for the trade chemotherapy drug Zydelig®. In some cases, health care professionals may use the trade name Zydelig® when referring to the generic drug idelalisib. Drug type: Idelalisib is a targeted therapy.
What kind of drug is idelalisib?
This medication is used to treat certain types of cancer (such as chronic lymphocytic leukemia-CLL, follicular B-cell non-Hodgkin’s lymphoma, small lymphocytic lymphoma-SLL). Idelalisib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.
What is idelalisib used for?
Idelalisib is used along with another medication rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) in people whose cancer came back after receiving other cancer treatments.
What is Ibrutinib and idelalisib?
Ibrutinib, the first-in-class inhibitor of Bruton tyrosine kinase, and idelalisib, the first-in-class inhibitor of phosphatidylinositol 3-kinase. δ , have recently been approved for the treatment of several indolent B-cell malignancies.
Is Idelalisib cytotoxic?
Idelalisib is a targeted agent that potently inhibits PI3Kδ which is exclusively expressed in hematological cells. Bendamustine is a well-tolerated cytotoxic alkylating agent which has been extensively used for treatment of chronic lymphocytic leukemia (CLL).
When did rituximab become available?
It was approved by the Food and Drug Administration on November 26, 1997, for the indication of relapsed or refractory, CD-20 positive, B-cell, low-grade or follicular non-Hodgkin’s lymphoma Rituximab is the first monoclonal antibody approved for the treatment of cancer and the first single agent approved specifically …
Is chlorambucil a chemotherapy?
Chlorambucil is a chemotherapy drug and is also known by its brand name Leukeran. It is used mainly to treat: chronic lymphocytic leukaemia (CLL) Non-Hodgkin lymphoma.
Can Ibrutinib cause liver damage?
Increased liver damage from ibrutinib will occur if not detected early, since it is metabolized in the liver by the P450 cytochrome enzyme CYP3A [16], and, therefore, drug levels will rise once liver damage has commenced.
What are the side effects of the drug Ibrutinib?
More common
- Belching.
- decreased appetite.
- difficulty having a bowel movement.
- heartburn or indigestion.
- muscle stiffness or spasms.
- small red or purple spots on the skin.
- stomach discomfort, upset, or pain.
- swelling or inflammation of the mouth.
Who makes Copiktra?
Verastem Sells Copiktra to Secura for $311 Million to Focus on KRAS Therapies. Boston-based Verastem signed a definitive deal to sell its global commercial and development rights to Copiktra (duvelisib) to Henderson, Nevada and San Diego-based Secura Bio.
Who makes Zydelig?
23, 2014– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration ( FDA ) has approved Zydelig® (idelalisib) 150 mg tablets for the treatment of three B-cell blood cancers.